7f45
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Structure of an Anti-CRISPR protein== | ==Structure of an Anti-CRISPR protein== | ||
| - | <StructureSection load='7f45' size='340' side='right'caption='[[7f45]]' scene=''> | + | <StructureSection load='7f45' size='340' side='right'caption='[[7f45]], [[Resolution|resolution]] 3.52Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7F45 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7F45 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[7f45]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7F45 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7F45 FirstGlance]. <br> |
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7f45 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7f45 OCA], [https://pdbe.org/7f45 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7f45 RCSB], [https://www.ebi.ac.uk/pdbsum/7f45 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7f45 ProSAT]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7f45 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7f45 OCA], [https://pdbe.org/7f45 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7f45 RCSB], [https://www.ebi.ac.uk/pdbsum/7f45 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7f45 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | CRISPR-Cas systems are prokaryotic antiviral systems, and phages use anti-CRISPR proteins (Acrs) to inactivate these systems. Here we present structural and functional analyses of AcrIF5, exploring its unique anti-CRISPR mechanism. AcrIF5 shows binding specificity only for the target DNA-bound form of the crRNA-guided surveillance (Csy) complex, but not the apo Csy complex from the type I-F CRISPR-Cas system. We solved the structure of the Csy-dsDNA-AcrIF5 complex, revealing that the conformational changes of the Csy complex caused by dsDNA binding dictate the binding specificity for the Csy-dsDNA complex by AcrIF5. Mechanistically, five AcrIF5 molecules bind one Csy-dsDNA complex, which destabilizes the helical bundle domain of Cas8f, thus preventing subsequent Cas2/3 recruitment. AcrIF5 exists in symbiosis with AcrIF3, which blocks Cas2/3 recruitment. This attack on the recruitment event stands in contrast to the conventional mechanisms of blocking binding of target DNA. Overall, our study reveals an unprecedented mechanism of CRISPR-Cas inhibition by AcrIF5. | ||
| + | |||
| + | AcrIF5 specifically targets DNA-bound CRISPR-Cas surveillance complex for inhibition.,Xie Y, Zhang L, Gao Z, Yin P, Wang H, Li H, Chen Z, Zhang Y, Yang M, Feng Y Nat Chem Biol. 2022 Mar 17. pii: 10.1038/s41589-022-00995-8. doi:, 10.1038/s41589-022-00995-8. PMID:35301482<ref>PMID:35301482</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 7f45" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Feng Y]] | + | [[Category: Feng, Y]] |
| + | [[Category: Immune system]] | ||
| + | [[Category: Mixed alpha-beta structure]] | ||
| + | [[Category: Monomer]] | ||
Revision as of 10:31, 6 April 2022
Structure of an Anti-CRISPR protein
| |||||||||||
